TAK Insider Trading Activity and SEC Form 4 Filings
TAK insider trading summary
Over the past 12 months, insiders at Takeda Pharmaceutical Co Ltd (TAK) reported 22 sales worth $15.2M by 13 insiders and no open-market purchases on SEC Form 4. Net insider selling was $15.2M.
Latest TAK insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 4, 2026 | Giles Richard Platford | President, IBU | Sell | $1.2M (55,617 @ $20.90) |
| Nov 2, 2026 | Teresa Marie Bitetti | President, OBU | Sell | $974K (46,609 @ $20.89) |
| Sep 14, 2026 | Lauren Rusckowski Duprey | Chief Transformation Officer | Sell | $640K (34,535 @ $18.54) |
| Sep 2, 2026 | Andrew Stewart Plump | President, R&D | Sell | $2.1M (116,191 @ $18.49) |
| Aug 19, 2026 | Andrew Stewart Plump | President, R&D | Sell | $363K (19,651 @ $18.49) |
| Aug 18, 2026 | Nicola Deidre Petal Greenway | Chief Human Resources Officer | Sell | $235K (12,980 @ $18.11) |
| Aug 11, 2026 | Elaine Mary Shannon | Pres., Global Supply & Quality | Sell | $357K (20,363 @ $17.55) |
| Aug 10, 2026 | Nicola Deidre Petal Greenway | Chief Human Resources Officer | Sell | $116K (6,774 @ $17.10) |
| Aug 10, 2026 | Giles Richard Platford | President, IBU | Sell | $532K (31,083 @ $17.10) |
| Aug 10, 2026 | Nicola Deidre Petal Greenway | Chief Human Resources Officer | Sell | $589K (33,628 @ $17.51) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.